SHIPPEO
Shippeo , a global leader in real-time transportation visibility, announces today it’s expanding its North American operations and U.S. executive team, as well as enhancing its customer-centric, multi-modal visibility platform. The systemwide enhancements will support global customers and the company’s growing North American customer base.
During this time of supply chain disruption, when visibility data is a lifeline enabling companies to proactively manage freight flows, Shippeo will accelerate the number of secure, direct integrations with U.S.-based trucking companies, logistics providers and ocean carriers, and have access to data from their terminal and port operator trading partners. This will build out Shippeo’s comprehensive, global, neutral partner network to augment the flow of visibility data to customers.
Shippeo’s presence in North America has uncovered an underserved aspect of the market’s visibility offerings, the customer-centric supply chain. By putting customers and their ecosystem of suppliers first, Shippeo has achieved a dominant leadership position in Europe and the Middle East with over 130 customers, including global brands such as, Coca-Cola, Schneider Electric, Sappi, Kuehne + Nagel, ThyssenKrupp and Saint-Gobain. In addition, 97% of Shippeo’s customers on Gartner Peer Insights would recommend the Shippeo Visibility Platform.*
Shippeo’s aim is to provide customers with the critical visibility data needed to increase operational agility and efficiency, strengthen their company’s supply chain execution and deliver a better experience for their customers.
Joining Shippeo’s executive team are industry heavyweights, Christopher Mazza and Brian Shultz, who will head-up Shippeo’s U.S.-based growth initiative.
Christopher P. Mazza, Shippeo Senior Vice President of International Growth, will lead Shippeo’s expansion in North America and new markets. Chris has extensive knowledge and experience with freight and logistics technology solutions having held senior leadership roles with ClearMetal (acquired by Project44), XVELA (Navis), and International Assets Systems (acquired by Blume Global). In addition, Chris has served in operational and executive management positions with major ocean carriers including, Maersk, DSR-Senator and Hanjin.
Brian Shultz, Vice President Sales & Marketing, Americas, has been working in the international supply chain technology space for more than 20 years. He’s created and managed large logistics networks comprising all modes of transportation for logistics service providers, beneficial cargo owner (BCO) shippers (across multiple verticals), 3PLs and 4PLs. Brian has held senior leadership roles within ABB, International Assets Systems (acquired by Blume Global) and Navis (acquired by Accel-KKR), in addition to years of international supply chain consulting.
“There is no better time than now to accelerate Shippeo’s position within the North American market. Visibility data analytics is vital to helping companies proactively manage supply chain issues, especially now, as ongoing market and infrastructure challenges continue to disrupt transportation flows and reliable logistics processes. We’re excited to deliver enhanced, innovative Shippeo visibility solutions to support and strengthen our global customers and North American companies,” said Lucien Besse, COO at Shippeo .
* Gartner Disclaimer: As of February 2nd 2022 based on 92 reviews in the Real-Time Transportation Visibility Platforms market. Gartner does not endorse any vendor, product or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220208005844/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom